Wiskott-Aldrich syndrome protein is an effector of Kit signaling

Blood

Volumn 114, Issue 14, 2009, Pages 2900-2908

  Mani, Maheswaran ^a   Venkatasubrahmanyam, Shivkumar ^a   Sanyal, Mrinmoy ^a   Levy, Shoshana ^a   Butte, Atul ^a   Weinberg, Kenneth ^a   Jahn, Thomas ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ACTIN RELATED PROTEIN 2; ACTIN RELATED PROTEIN 3; CALCIUM ION; GROWTH FACTOR; STEM CELL FACTOR; WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CALCIUM CELL LEVEL; CELL COUNT; CELL CULTURE; CELL SIZE; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; EFFECTOR CELL; FEMALE; FILOPODIUM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HETEROZYGOTE; HUMAN; HUMAN CELL; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL; WILD TYPE; WISKOTT ALDRICH SYNDROME;

ACTIN-RELATED PROTEIN 2; ANIMALS; BONE MARROW; CALCIUM; CARRIER PROTEINS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MAST CELLS; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; PSEUDOPODIA; SIGNAL TRANSDUCTION; STEM CELL FACTOR; TYROSINE; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 70449497348     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-200733     Document Type: Article

References (67)

1. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell. 1988;55:185-192.
2. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988;335:88-89. (Pubitemid 18220260)
3. Cable J, Huszar D, Jaenisch R, Steel KP. Effects of mutations at the W locus (c-kit) on inner ear pigmentation and function in the mouse. Pigm Cell Res. 1994;7:17-32.
4. Gore BB, Wong KG, Tessier-Lavigne M. Stem cell factor functions as an outgrowth-promoting factor to enable axon exit from the midline intermediate target. Neuron. 2008;57:501-510. (Pubitemid 351273993)
5. Milenkovic N, Frahm C, Gassmann M, et al. Nociceptive tuning by stem cell factor/c-Kit signaling. Neuron. 2007;56:893-906. (Pubitemid 350181357)
6. Matsui Y, Zsebo KM, Hogan BL. Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature. 1990;347:667-669. (Pubitemid 20356242)
7. Copeland NG, Gilbert DJ, Cho BC, et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell. 1990;63:175-183. (Pubitemid 20359515)
8. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J. 1991;10:4121-4128. (Pubitemid 21905443)
9. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P. Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J. 1995;14:473-483.
10. Scott G, Liang H, Luthra D. Stem cell factor regulates the melanocyte cytoskeleton. Pigm Cell Res. 1996;9:134-141. (Pubitemid 126482944)
11. Vosseller K, Stella G, Yee NS, Besmer P. c-kit receptor signaling through its phosphatidylinositide-3′-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling. Mol Biol Cell. 1997;8:909-922. (Pubitemid 27255030)
12. Samayawardhena LA, Kapur R, Craig AW. Involvement of Fyn kinase in Kit and integrin-mediated Rac activation, cytoskeletal reorganization, and chemotaxis of mast cells. Blood. 2007;109:3679-3686. (Pubitemid 46641716)
13. Symons M, Derry JM, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996;84:723-734. (Pubitemid 26094202)
14. Moreau V, Frischknecht F, Reckmann I, et al. A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization. Nat Cell Biol. 2000;2:441-448. (Pubitemid 30781070)
15. Yarar D, To W, Abo A, Welch MD. The Wiskott-Aldrich syndrome protein directs actin-based motility by stimulating actin nucleation with the Arp2/3 complex. Curr Biol. 1999;9:555-558. (Pubitemid 29257114)
16. Rohatgi R, Ma L, Miki H, et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 1999;97:221-231. (Pubitemid 129746811)
17. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J. 1998;17:6932-6941. (Pubitemid 28550287)
18. Machesky LM, Mullins RD, Higgs HN, et al. Scar, a WASp-related protein, activates nucleation of actin filaments by the Arp2/3 complex. Proc Natl Acad Sci U S A. 1999;96:3739-3744.
19. Wiskott A. Familial congenital Morbus Werlhofii [German]? Monatsschr Kinderheilkd. 1937;68:212-216.
20. Aldrich RA, Steinberg AG, Campbell DC. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics. 1954;13:133-139.
21. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;79:922ff. (Pubitemid 24268586)
22. Derry JM, Kerns JA, Weinberg KI, et al. WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Hum Mol Genet. 1995;4:1127-1135.
23. Cooper MD, Chae HP, Lowman JT, Krivit W, Good RA. Wiskott-Aldrich syndrome: an immunologic deficiency disease involving the afferent limb of immunity. Am J Med. 1968;44:499-513.
24. Binder V, Albert MH, Kabus M, Bertone M, Meindl A, Belohradsky BH. The genotype of the original Wiskott phenotype. N Engl J Med. 2006;355:1790-1793.
25. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980;55:243-252. (Pubitemid 10161198)
26. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity. 1998;9:81-91. (Pubitemid 28361297)
27. Rawlings SL, Crooks GM, Bockstoce D, Barsky LW, Parkman R, Weinberg KI. Spontaneous apoptosis in lymphocytes from patients with Wiskott-Aldrich syndrome: correlation of accelerated cell death and attenuated bcl-2 expression. Blood. 1999;94:3872-3882.
28. Kolluri R, Tolias KF, Carpenter CL, Rosen FS, Kirchhausen T. Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci U S A. 1996;93:5615-5618. (Pubitemid 26159500)
29. Ramesh N, Anton IM, Hartwig JH, Geha RS. WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells. Proc Natl Acad Sci U S A. 1997;94:14671-14676. (Pubitemid 28041432)
30. Machesky LM, Insall RH. Scar1 and the related Wiskott-Aldrich syndrome protein, WASP, regulate the actin cytoskeleton through the Arp2/3 complex. Curr Biol. 1998;8:1347-1356.
31. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature. 2000;404:151-158. (Pubitemid 30154475)
32. Rozelle AL, Machesky LM, Yamamoto M, et al. Phosphatidylinositol 4,5-bisphosphate induces actin-based movement of raft-enriched vesicles through WASP-Arp2/3. Curr Biol. 2000;10:311-320. (Pubitemid 30186134)
33. Dupré L, Aiuti A, Trifari S, et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity. 2002;17:157-166. (Pubitemid 35245958)
34. Fearon ER, Kohn DB, Winkelstein JA, Vogelstein B, Blaese RM. Carrier detection in the Wiskott Aldrich syndrome. Blood. 1988;72:1735-1739. (Pubitemid 18268660)
35. Wengler G, Gorlin JB, Williamson JM, Rosen FS, Bing DH. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood. 1995;85:2471-2477.
36. Avanzi GC, Brizzi MF, Giannotti J, et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. J Cell Physiol. 1990;145:458-464. (Pubitemid 120027384)
37. Jahn T, Leifheit E, Gooch S, Sindhu S, Weinberg K. Lipid rafts are required for Kit survival and proliferation signals. Blood. 2007;110:1739-1747. (Pubitemid 47443883)
38. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
39. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
40. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121. (Pubitemid 32397092)
41. Miki H, Nonoyama S, Zhu Q, Aruffo A, Ochs HD, Takenawa T. Tyrosine kinase signaling regulates Wiskott-Aldrich syndrome protein function, which is essential for megakaryocyte differentiation. Cell Growth Differ. 1997;8:195-202. (Pubitemid 27068897)
42. Pivniouk VI, Snapper SB, Kettner A, et al. Impaired signaling via the high-affinity IgE receptor in Wiskott-Aldrich syndrome protein-deficient mast cells. Int Immunol. 2003;15:1431-1440. (Pubitemid 37536744)
43. Huber M, Helgason CD, Scheid MP, Duronio V, Humphries RK, Krystal G. Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. EMBO J. 1998;17:7311-7319. (Pubitemid 29002700)
44. Sivalenka RR, Jessberger R. SWAP-70 regulates c-kit-induced mast cell activation, cell-cell adhesion, and migration. Mol Cell Biol. 2004;24:10277-10288. (Pubitemid 39507866)
45. Simon HU, Mills GB, Hashimoto S, Siminovitch KA. Evidence for defective transmembrane signaling in B cells from patients with Wiskott-Aldrich syndrome. J Clin Invest. 1992;90:1396-1405.
46. Zhang J, Shehabeldin A, da Cruz LAG, et al. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med. 1999;190:1329-1342. (Pubitemid 29522216)
47. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517-529.
48. Cory GO, Garg R, Cramer R, Ridley AJ. Phosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation. J Biol Chem. 2002;277:45115-45121. (Pubitemid 36159113)
49. Cory GO, Cramer R, Blanchoin L, Ridley AJ. Phosphorylation of the WASP-VCA domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by WASP. Mol Cell. 2003;11:1229-1239. (Pubitemid 36645142)
50. Tsuboi S, Meerloo J. Wiskott-Aldrich syndrome protein is a key regulator of the phagocytic cup formation in macrophages. J Biol Chem. 2007;282:34194-34203. (Pubitemid 350159472)
51. Guinamard R, Aspenstrom P, Fougereau M, Chavrier P, Guillemot JC. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42. FEBS Lett. 1998;434:431-436. (Pubitemid 29052271)
52. Baba Y, Nonoyama S, Matsushita M, et al. Involvement of Wiskott-Aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway. Blood. 1999;93:2003-2012. (Pubitemid 29128503)
53. Badour K, Zhang J, Shi F, Leng Y, Collins M, Siminovitch KA. Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J Exp Med. 2004;199:99-112. (Pubitemid 38076482)
54. Banin S, Truong O, Katz DR, Waterfield MD, Brickell PM, Gout I. Wiskott-Aldrich syndrome protein (WASp) is a binding partner for c-Src family protein-tyrosine kinases. Curr Biol. 1996;6:981-988. (Pubitemid 26350718)
55. Timokhina I, Kissel H, Stella G, Besmer P. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 1998;17:6250-6262. (Pubitemid 28497798)
56. Agosti V, Corbacioglu S, Ehlers I, et al. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med. 2004;199:867-878. (Pubitemid 38375206)
57. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23:7957-7968. (Pubitemid 39468854)
58. Dong X, Patino-Lopez G, Candotti F, Shaw S. Structure-function analysis of the WIP role in T cell receptor-stimulated NFAT activation: evidence that WIP-WASP dissociation is not required and that the WIP NH2 terminus is inhibitory. J Biol Chem. 2007;282:30303-30310. (Pubitemid 350035300)
59. Rodal AA, Sokolova O, Robins DB, et al. Conformational changes in the Arp2/3 complex leading to actin nucleation. Nat Struct Mol Biol. 2005;12:26-31. (Pubitemid 40082913)
60. LeClaire LL III, Baumgartner M, Iwasa JH, Mullins RD, Barber DL. Phosphorylation of the Arp2/3 complex is necessary to nucleate actin filaments. J Cell Biol. 2008;182:647-654.
61. Cotta-de-Almeida V, Westerberg L, Maillard MH, et al. Wiskott Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development. Proc Natl Acad Sci U S A. 2007;104:15424-15429. (Pubitemid 47502933)
62. 2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor. J Biol Chem. 1997;272:30519-30525.
63. 2+ channels in intestinal pacing in wild-type and W/W(V) mice. Am J Physiol. 2005;288:G439-G446.
64. Lacout C, Haddad E, Sabri S, et al. A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood. 2003;102:1282-1289. (Pubitemid 36988034)
65. Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood. 2008;112:4139-4147.
66. Santilli G, Thornhill SI, Kinnon C, Thrasher AJ. Gene therapy of inherited immunodeficiencies. Expert Opin Biol Ther. 2008;8:397-407.
67. Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008;8:181-190. (Pubitemid 351233711)